CompletedPhase 4

Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding

China216 participantsStarted 2012-02

Plain-language summary

This double-blind, randomized trial aims to evaluate whether uninterrupted anti-platelet therapy (clopidogrel) will increase the risk of bleeding associated with removal of polyp during colonoscopy in patients with coronary artery disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. On regular treatment with clopidogrel alone or in combination with other anti-platelet drugs (e.g. aspirin)
✓. Elective colonoscopy for asymptomatic screening of bowel cancer or investigation of bowel symptoms (e.g. altered bowel habit, rectal bleeding, anemia, polyp follow-up)
✓. Age ≥ 18
✓. Written informed consent

Exclusion criteria

✕. Coronary stent of any type placed within 30 days
✕. Cardiac-vascular event within 3 months
✕. Drug-eluting coronary stent placed within 6 months
✕. Terminal illness
✕. Concomitant use of anticoagulants
✕. Congenital or acquired bleeding diathesis showing clinical bleeding tendency (e.g. hemophilia, decompensated cirrhosis)
✕. Pregnancy or women of child-bearing age without regular use of contraception

What they're measuring

Delayed post-polypectomy bleeding

Timeframe: 30 days post-colonoscopy

Trial details

NCT IDNCT01806090

SponsorChinese University of Hong Kong

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-04

View on ClinicalTrials.gov More Gastrointestinal Bleeding trials